sutthirat sutthisumdang
Baird initiated coverage of Bright Minds Biosciences (NASDAQ:DRUG) with an outperform rating, citing the planned acquisition of rival Longboard Pharmaceuticals (LBPH).
Bright Minds’ (DRUG) lead agent, BMB-101, is a 5-HT2C agonist entering Phase 2 testing for developmental epileptic encephalopathy, or DEE, and absence